CALIFORNIA, US. June 4, 2026 – Sapyen, a global leader in male fertility diagnostics, has entered into a strategic partnership with My Surrogacy Journey, a widely respected international surrogacy organization. Through this collaboration, the two companies will work together to provide intended parents with greater access to fertility testing and reproductive health support, beginning with a rollout across the United States.
Under the partnership, Sapyen will serve as a fertility diagnostics partner for My Surrogacy Journey and its intended parents worldwide, offering services including semen analysis, DNA fragmentation testing, and infectious disease screening.
The collaboration brings together two organizations that are playing an increasingly influential role in the evolution of reproductive healthcare on a global scale.
For many years, male fertility testing and preservation services have been limited by fragmented systems, clinic-based processes, high costs, and logistical challenges, particularly for patients navigating care across multiple countries. These complexities are often amplified in surrogacy journeys, where intended parents may need to coordinate with laboratories, clinics, legal professionals, and service providers across different jurisdictions.
Both organizations share the view that the future of fertility care will be driven by integrated global infrastructure rather than isolated services, enabling patients to move more efficiently through reproductive pathways regardless of location.
My Surrogacy Journey has established itself as a leading force in international surrogacy through its carefully curated global network, commitment to ethical practices, patient advocacy, and ability to manage complex cross-border journeys. The organization is widely recognized by intended parents and fertility professionals for bringing greater transparency, consistency, and operational excellence to a sector that has historically lacked standardization.
Sapyen has also emerged as a significant infrastructure provider within fertility diagnostics. The company works with fertility clinics, laboratory networks, and healthcare organizations worldwide to deliver advanced at-home semen analysis, DNA fragmentation testing, infectious disease screening, and reproductive preservation solutions.
Its proprietary SPX72 stabilization technology extends the viability of analyzable semen samples from roughly one hour to as long as 72 hours, making laboratory-grade testing and preservation possible without the limitations of traditional clinic-based collection.
“The historical fertility model was built around geography,” said Ash Ramachandran, Founder and CEO of Sapyen. “Patients travelled to infrastructure. The next generation of reproductive medicine will invert that entirely.”
The partnership will initially launch throughout the United States, with plans to explore additional collaboration opportunities in fertility preservation and broader reproductive health services over time.
“Surrogacy is one of the most operationally complex categories in reproductive medicine,” Ramachandran continued. “It requires coordination across clinicians, laboratories, legal teams, donors, intended parents, and international jurisdictions simultaneously. Infrastructure quality materially impacts patient outcomes in that environment.
“My Surrogacy Journey has built one of the most sophisticated and trusted platforms globally for navigating that complexity. They are not simply facilitating introductions. They are helping define the operational and ethical standard for modern surrogacy internationally.”
Ramachandran noted that fertility diagnostics and preservation are becoming increasingly central to reproductive healthcare rather than supplementary services.
“For decades, fertility testing and preservation were positioned as reactive services. By the time many patients entered the system, optionality had already narrowed. We believe that changes now. Earlier diagnostics, better biological data, and accessible preservation infrastructure will increasingly become standard entry points into reproductive medicine globally.”
Michael Johnson-Ellis, Co-founder and Co-CEO of My Surrogacy Journey, said the partnership aligns with the organization’s commitment to building a comprehensive support ecosystem for intended parents around the world.
“Our responsibility to intended parents extends far beyond guidance. We are building an ecosystem around them capable of supporting extraordinarily complex journeys with consistency, credibility, and care.
“Sapyen immediately distinguished itself with both its scientific credibility and operational capability to execute fertility diagnostics and preservation at international scale.
“Their infrastructure, laboratory integration, and long-term vision for modern fertility care make them an exceptionally strong partner for My Surrogacy Journey and for the families we support across the world.”
Wes Johnson-Ellis, Co-founder and Co-CEO of My Surrogacy Journey, added that increasingly international fertility journeys require solutions that can function seamlessly across borders.
“Intended parents today are navigating fertility across multiple countries and healthcare systems simultaneously. That requires partners capable of operating with precision internationally. This partnership materially strengthens the level of fertility support available to intended parents navigating increasingly global reproductive pathways.”
The agreement further expands Sapyen’s international presence in fertility diagnostics and reproductive preservation, building on its continued growth across IVF clinic networks, laboratory organizations, benefits providers, and reproductive healthcare partners worldwide.
